About
Formed via Ocuphire Pharma's all-stock acquisition of Opus Genetics (Oct 2024), transforming the public shell (Nasdaq: IRD) into a gene-therapy-focused company. Patient enrollment in the Phase 3 LCA5 trial completed Aug 2026.
HQ: Research Triangle Park, NC, USA
Funding
Up to $155M Oberland Capital facility (Apr 2026) + $25M placement (Feb 2026) + $20M+ offering (Mar 2025)
~$40M drawn at closing; cash ~$100M.